Skip to main content
Caplight Logo









Eccogene

Eccogene

Private
ShanghaiHealthcare & Life Scienceshttps://www.eccogene.com/

Last Round

Strategic

Nov 9, 2023

Est. Valuation

$498M

Total Funding Raised

$238.8M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Eccogene is a clinical-stage biopharmaceutical company that develops next-generation oral small molecule therapeutics for chronic cardiometabolic and inflammatory conditions.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticaldrug discoverysmall molecule therapeuticsGLP-1 receptor agonistGLP-1metabolic diseaseobesity treatmenttype 2 diabetesoral weight loss drugsDGAT2 inhibitorTHR-beta agonistbiotech licensingclinical-stage biotechinflammatory diseasepharma partnership

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Eccogene Comparables

Compare Eccogene with similar companies based on industry and business-model similarity.

Eccogene comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Regor Therapeutics Group
86%
Kailera Therapeutics
84%
Structure Therapeutics
84%

Eccogene Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
StrategicNov 9, 2023
Series BJun 11, 2023
Series A ExtensionDec 22, 2020
Series ASep 7, 2018

Key People

Founding team and executive leadership

Jingye Zhou

Co-founder And CEO

Founding Team

Eccogene Investors

Notable investors and investment history

Eccogene investors
InvestorRounds
New Alliance CapitalSeries B
TF CapitalSeries A
健壹资本Series A
Huajin CapitalSeries B
Huagai CapitalSeries A Extension
Qingsong CapitalSeries B, Series A Extension
Oriza Seed Venture CapitalSeries B, Series A Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 25, 2026

    Monthly visitors grew 52% MoM.

  • Apr 8, 2026

    Job posting indicates company is pre-IPO.

Eccogene Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Eccogene Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Eccogene's valuation, stock price, and market status.

Firmographic Details

HeadquartersShanghai
Employee Range33
Year Founded2018
Last FundingNov 9, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?